Telix boosts in-house radiopharma manufacturing; Dynavax improves vaccine production costs

29 Feb 2024

VaccineAcquisition

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential updates on new builds, collaborations, recalls and more. Telix Pharmaceuticals is acquiring Texas-based radiopharma and bioconjugate company IsoTherapeutics in a deal that includes $8 million up front. This will bring manufacturing in-house for Australian biotech Telix, according to a Tuesday release. Dynavax Technologies touted its decreasing manufacturing costs per unit for its hepatitis B vaccine HEPLISAV-B, attributing this to “a number of investments in manufacturing,” said CFO Kelly MacDonald during an investor call on Feb. 22. The company made investments at its antigen manufacturing facility in Düsseldorf, Germany, which has helped the company to improve its yield of HEPLISAV-B.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Telix d.o.o.Dynavax GmbH

Telix Pharmaceuticals Ltd.

[+2]

Indications

Targets

Drugs

Hepatitis B vaccine(Takeda Pharmaceutical Co., Ltd.)Adjuvanted Hepatitis B vaccine (Recombinant)(Dynavax Technologies Corp.)

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.